Literature DB >> 20381408

Current trends and future perspectives in the surgical management of oral cancer.

Nicholas Kalavrezos1, Rishi Bhandari.   

Abstract

Surgery remains the frontline treatment for oral cancer. Factors affecting the surgical management are related to the staging of the primary disease and the presence of regional or distant metastasis. Histopathological parameters such as tumour grade, depth and pattern of invasion are of paramount importance for the extent of the surgical treatment. Surgery of the neck is evolving to more selective treatments and the concept of sentinel lymph node biopsy is gradually been established in the management of the neck for early oral cancer. Reconstruction of the defect is mainly performed with free flaps. Further refinement in the flap selection and harvesting techniques will lead to free-style flap reconstruction, minimising the morbidity of the donor site and increasing the versatility of reconstruction at the recipient site. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20381408     DOI: 10.1016/j.oraloncology.2010.03.007

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  23 in total

1.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

Review 2.  Surgical margins and its evaluation in oral cancer: a review.

Authors:  Spoorthi Banvar Ravi; Saileela Annavajjula
Journal:  J Clin Diagn Res       Date:  2014-09-20

3.  Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.

Authors:  Arti Yadav; Bhavna Kumar; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2011-05-06       Impact factor: 6.261

4.  IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway.

Authors:  Arti Yadav; Bhavna Kumar; Jharna Datta; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Res       Date:  2011-10-05       Impact factor: 5.852

5.  Simple Endoscopic Method of Scoring Swallowing Function After Treatment in Advanced Head and Neck Cancer Patients.

Authors:  Akira Ohkoshi; Takenori Ogawa; Kengo Kato; Ayako Nakanome; Ryo Ishii; Takuya Yoshida; Yuki Nakayama; Yukio Katori
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-02-08

6.  Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis.

Authors:  Pawan Kumar; Arti Yadav; Samip N Patel; Mozaffarul Islam; Quintin Pan; Sofia D Merajver; Theodoros N Teknos
Journal:  Mol Cancer       Date:  2010-08-03       Impact factor: 27.401

7.  YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.

Authors:  Bhavna Kumar; Arti Yadav; James C Lang; Michael J Cipolla; Alessandra C Schmitt; Nicole Arradaza; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2012-06-21       Impact factor: 6.009

8.  Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog.

Authors:  Bhavna Kumar; Arti Yadav; James C Lang; Theodoros N Teknos; Pawan Kumar
Journal:  Genes Cancer       Date:  2015-03

9.  Tumor-Associated Endothelial Cells Promote Tumor Metastasis by Chaperoning Circulating Tumor Cells and Protecting Them from Anoikis.

Authors:  Arti Yadav; Bhavna Kumar; Jun-Ge Yu; Matthew Old; Theodoros N Teknos; Pawan Kumar
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

10.  Prognostic significance of p53 immunoexpression in the survival of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy.

Authors:  Li Li; Manabu Fukumoto; Duo Liu
Journal:  Oncol Lett       Date:  2013-10-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.